The Emerging Melanoma Management: Historical Perspective to Future Directions
Cancers · 17.03.2026 · 18 (6) · 968
DOI: 10.3390/cancers18060968 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.03.2026. Verfasst von Shin Yee Hui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University …. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United College Endowment Fund Research Grant Scheme, Research Grants Council-General Research Fund, CUHK Knowledge Transfer Committee-IdeaBooster Fund.
Abstract (Originalsprache)
Cutaneous melanoma is an aggressive form of cancer that accounts for approximately 80% of skin cancer-associated mortality. Treatment strategies for melanoma have been rapidly evolving over the past two decades. Clinical outcomes for advanced melanoma patients have improved with the use of immune checkpoint inhibitors and targeted therapies, including combination therapies. In this review, we primarily focus on the evolution of novel therapies for advanced melanoma patients, existing and emerging melanoma biomarkers, and the most up-to-date treatment recommendations. Furthermore, we summarise ongoing studies, clinical trials, and emerging therapeutic strategies. In this review, we will walk you through how cutaneous melanoma treatment strategies have evolved over the past 50 years. We will provide background on how those strategies were developed, how they function, their pros and cons, and their performance in terms of clinical benefits. Lastly, we will provide insights into potential therapies and research areas. In summary, improving the efficacy of immune checkpoint blockade remains the most promising approach for improving cutaneous melanoma management. However, strategies such as CAR-T/NK, PROTAC, or extracellular vesicle-based therapies are also worth further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
- Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Dermatology, Medical University of Vienna, 1090 Vienna, Austria.
- Frazer Institute, The University of Queensland, Brisbane, QLD 4072, Australia.
ORCID-Profile: Shin Yee Hui, Nikolas K Haass, Shweta Tikoo, Dajiang Guo
Förderung
- United College Endowment Fund Research Grant Scheme
- Research Grants Council-General Research Fund
- CUHK Knowledge Transfer Committee-IdeaBooster Fund
- United College Endowment Fund Research
Zitieren
APA
Hui, S. Y., Jain, R., Haass, N. K., Weninger, W., Tikoo, S., & Guo, D. (2026). The Emerging Melanoma Management: Historical Perspective to Future Directions. Cancers, 18(6), 968. https://doi.org/10.3390/cancers18060968
Vancouver
Hui SY, Jain R, Haass NK, Weninger W, Tikoo S, Guo D. The Emerging Melanoma Management: Historical Perspective to Future Directions. Cancers. 2026;18(6):968. doi:10.3390/cancers18060968
BibTeX
@article{Hui2026,
author = {Hui, Shin Yee and Jain, Rohit and Haass, Nikolas K and Weninger, Wolfgang and Tikoo, Shweta and Guo, Dajiang},
title = {The Emerging Melanoma Management: Historical Perspective to Future Directions},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {968},
doi = {10.3390/cancers18060968}
}
EUVIMED